Research progress on donor-derived cell-free DNA as a potential rejection biomarker in kidney transplantation
Kidney diseases have become a global public health issue.Patients with end-stage renal disease rely on dialysis or kidney transplantation for treatment,with kidney transplantation being the best option.Kidney transplantation improves the quality of life and prolongs survival,but some patients experience early graft loss due to immune or non-immune factors,meaning not all patients fully benefit from transplantation.Circulating free DNA(cfDNA)refers to small fragments of DNA found in bodily fluids such as blood,typically originating from various tissues.Donor-derived cfDNA(dd-cfDNA)is the exogenous cfDNA from the transplanted organ.Unlike invasive biopsy,dd-cfDNA can be detected through non-invasive analysis of samples.The concentration of dd-cfDNA may increase even before creatinine levels rise,assisting in the early diagnosis of graft injury and providing an opportunity for early intervention to prevent premature graft loss.This review summarizes research on the role of cfDNA in kidney transplantation and aims to provide a reference for the widespread clinical application of dd-cfDNA testing.
万方数据
维普
